Search results for: 'rare rate'

Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emerging as disease-modifying approaches addressing the ...

The increasing demand for data and the emergence of the connected ecosystem are driving data center operators and other service providers to upgrade capacities and capabilities, intensifying the need to ensure the integrity and accuracy of data systems. This, in turn, is fueling the demand for testing and measurement equipment such as the bit error...

Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...

25 Jun 2019  |  North America  |  Market Research

Global Rare Earth Materials Market, Forecast to 2025

The Rise in Neodymium Magnet, Lanthanum and Cerium-based Application Demand Contributes to Noteworthy Market Growth

Infographics

×

Key Issues Addressed

The seventeen rare-earth elements are cerium (Ce), dysprosium (Dy), erbium (Er), europium (Eu), gadolinium (Gd), holmium (Ho), lanthanum (La), lutetium (Lu), neodymium (Nd), praseodymium (Pr), promethium (Pm), samarium (Sm), scandium (Sc), terbium (Tb), thulium (Tm), ytterbium (Yb), and yttrium (Y). They find important applications in various indus...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

09 Nov 2022  |  Global  |  Technology Research

Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis

Strategic partnering and new product development will enable better biologics for personalized and targeted treatment

Infographics

×

Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies. NMDs prese...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides innovation insights across cell and gene therapy advances. The TOE also encompasses recent therapy developments for neuropsychiatric, rare, and infectious diseases. The research covers recent advances in vaccines and biomanufacturing platforms.The Life ...

This research service covers the state of the global bit error rate test equipment (BERT) market, examining drivers and restraints for growth, end-user trends, application trends, and geographical trends. Revenue forecasts by market segment are included. In addition, an in-depth analysis of the competitive landscape, including vendor market shares,...

12 Aug 2020  |  North America  |  Market Research

New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025

AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities

Infographics

×

Key Issues Addressed

Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...